Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311
Hybridoma Technology01:31

Hybridoma Technology

17.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.2K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

208
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
208
Antibody Actions01:26

Antibody Actions

2.3K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacological management of elevated LDL in patients with hypercholesterolemia and mixed dyslipidaemia.

Expert opinion on pharmacotherapy·2026
Same author

Lipoprotein(a) - treatments in development.

Expert opinion on pharmacotherapy·2025
Same author

Statin-Related Transaminitis-Is It Necessary to Stop Statins?

Cardiovascular drugs and therapy·2025
Same author

Options for patients with out-of-control blood pressure: after all avenues have been exhausted.

Expert review of cardiovascular therapy·2024
Same author

Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors.

Journal of lipid and atherosclerosis·2024
Same author

Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date.

Expert opinion on pharmacotherapy·2023
Same journal

Vunakizumab for IL-17A-Mediated Diseases: A Review in Psoriasis and Spondyloarthritis.

Biologics : targets & therapy·2026
Same journal

Immunological Biomarkers in Glioblastoma: Targeting T and NK Cells for Enhanced Diagnosis and Prognosis.

Biologics : targets & therapy·2026
Same journal

MicroRNA-661 Suppresses Proliferation and Migration of Pulmonary Artery Smooth Muscle Cells and Endothelial Cells by Targeting CCND2.

Biologics : targets & therapy·2026
Same journal

Vunakizumab and Acitretin for Elderly Refractory Generalized Pustular Psoriasis: A Case Report and Comprehensive Literature Review.

Biologics : targets & therapy·2026
Same journal

Rapid Resolution of Psoriasis Following Low-Dose Interleukin-2 Monotherapy: A Case Report.

Biologics : targets & therapy·2026
Same journal

Long-Term TIE2 Inhibition in a TEK-Mutated Venous Malformation: A 3-Year Clinical Experience.

Biologics : targets & therapy·2026
See all related articles

Related Experiment Video

Updated: Jan 12, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.5K

Antibody-Based Therapeutics for Hypercholesterolemia.

Brian Tomlinson1, Paul Chan2

  • 1Faculty of Medicine, Macau University of Science & Technology, Macau, 999078, People's Republic of China.

Biologics : Targets & Therapy
|November 3, 2025
PubMed
Summary
This summary is machine-generated.

Monoclonal antibodies targeting PCSK9, ANGPTL3, and ANGPTL4 offer new treatments for hypercholesterolemia when statins fail. These advanced therapies reduce LDL cholesterol and cardiovascular risk in high-risk patients.

Keywords:
angiopoietin-like 3atherosclerotic cardiovascular diseasefamilial hypercholesterolemiamonoclonal antibodyproprotein convertase subtilisin/kexin type 9

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.3K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.0K

Related Experiment Videos

Last Updated: Jan 12, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.5K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.3K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.0K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biotechnology

Background:

  • Statins and ezetimibe are first-line treatments for hypercholesterolemia, but often insufficient to reach low-density lipoprotein (LDL) cholesterol goals.
  • Residual cardiovascular risk persists in patients with uncontrolled LDL cholesterol despite standard oral therapies.

Purpose of the Study:

  • To review monoclonal antibodies (mAbs) developed to address residual cardiovascular risk associated with uncontrolled LDL cholesterol.
  • To discuss novel mAbs targeting PCSK9, ANGPTL3, and ANGPTL4 for hypercholesterolemia management.

Main Methods:

  • Review of scientific literature on monoclonal antibodies for hypercholesterolemia treatment.
  • Analysis of efficacy and safety data for PCSK9, ANGPTL3, and ANGPTL4 inhibitors.

Main Results:

  • PCSK9 inhibitors (alirocumab, evolocumab) are effective and safe for high-risk patients not achieving LDL goals.
  • Newer PCSK9 mAbs approved in China offer less frequent dosing.
  • Evinacumab (ANGPTL3 inhibitor) is approved for homozygous familial hypercholesterolemia; other ANGPTL3 and ANGPTL4 mAbs are in development.

Conclusions:

  • Monoclonal antibodies represent a significant advancement in managing hypercholesterolemia and reducing cardiovascular risk.
  • Emerging therapies like antisense oligonucleotides and small interfering RNA may offer more cost-effective alternatives.
  • Further research is needed to establish long-term efficacy and broader indications for novel mAbs.